EUVIMEDEUVIMED entdecken
Multizentrische StudieRandomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Development in Left Ventricular Mass After Early and Late Conversion From Calcineurin Inhibitors to Everolimus in Heart Transplant Recipients—Results From Two Randomized Controlled Trials

Klaus Murbraech iD, Feben Tecklzig, Richard John Massey iD, Einar Gude iD, Finn Gustafsson iD, Hans Eiskjær iD, Kristjan Karason iD, Göran Rådegran iD, Arne K Andreassen, Lars Gullestad iD, Kaspar Broch iD

Clinical Transplantation · 2026-10 · 40 (10)

DOI: 10.1111/ctr.70705 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Clinical Transplantation, online erschienen am 09.10.2026. Verfasst von Klaus Murbraech und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Oslo University Hospital, Rikshospitalet, Oslo, Norway. Hauptthemen laut MEDLINE: Calcineurin Inhibitors, Everolimus, Graft Rejection, Heart Transplantation. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Novartis.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Left ventricular hypertrophy in heart transplant recipients has been attributed to the use of calcineurin inhibitors. We assessed left ventricular mass across treatment arms in 83 heart transplant recipients in the Scandinavian heart transplant everolimus de novo study with early calcineurin inhibitors avoidance (SCHEDULE), and in 75 maintenance recipients in the Nordic Certican Trial in Heart and Lung Transplantation (NOCTET). In SCHEDULE, we randomized participants to treatment with calcineurin inhibitors or replacement with everolimus within 7–11 weeks after transplant. In NOCTET, participants were randomized to treatment with calcineurin inhibitors or a combination of low dose calcineurin inhibitors and everolimus. We followed patients with echocardiography for 3 years in the SCHEDULE trial and for 5 years in NOCTET. In SCHEDULE, left ventricular mass diminished with time, particularly across the first year of follow‐up (everolimus arm: −10 ± 18 g/m 2 , cyclosporine arm: −9 ± 13 g/m 2 ). However, there was no between‐group difference in this development ( p = 0.91). In NOCTET, there was no significant change in LVM over time and no between‐group difference in the change ( p = 0.27). In conclusion, t he replacement of calcineurin inhibitors with everolimus or a reduction in the calcineurin inhibitor dose did not mitigate left ventricular hypertrophy after heart transplantation. Trial Registration SCHEDULE—ClinicalTrials.gov Identifier: NCT01266148; NOCTET—ClinicalTrials.gov Identifier: NCT00377962

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Calcineurin InhibitorsEverolimusGraft RejectionHeart TransplantationHypertrophy, Left VentricularFemaleHumansMaleMiddle AgedFollow-Up StudiesGraft SurvivalImmunosuppressive AgentsPrognosisRisk Factors

Stichwörter der Autor:innen

calcineurin inhibitorsheart transplantationleft ventricular hypertrophy

Substanzen

Calcineurin InhibitorsEverolimusImmunosuppressive Agents

Autor:innen und Institutionen

  • Department of Cardiology, Oslo University Hospital, Rikshospitalet, Oslo, Norway.
  • Faculty of Medicine, University of Oslo, Oslo, Norway.
  • KG Jebsen Center For Cardiac Research and Center for Heart Failure Research, University of Oslo, Oslo, Norway.
  • Department of Cardiology, Rigshospitalet, Copenhagen, Denmark.
  • Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark.
  • Transplant Institute, Sahlgrenska University Hospital, Gothenburg, Sweden.

ORCID-Profile: Klaus Murbraech, Richard John Massey, Einar Gude, Finn Gustafsson, Hans Eiskjær, Kristjan Karason, Göran Rådegran, Lars Gullestad, Kaspar Broch

Förderung

  • Novartis

Zitieren

APA

Murbraech, K., Tecklzig, F., Massey, R. J., Gude, E., Gustafsson, F., Eiskjær, H., Karason, K., Rådegran, G., Andreassen, A. K., Gullestad, L., & Broch, K. (2026). Development in Left Ventricular Mass After Early and Late Conversion From Calcineurin Inhibitors to Everolimus in Heart Transplant Recipients—Results From Two Randomized Controlled Trials. Clinical Transplantation, 40(10). https://doi.org/10.1111/ctr.70705

Vancouver

Murbraech K, Tecklzig F, Massey RJ, Gude E, Gustafsson F, Eiskjær H, et al. Development in Left Ventricular Mass After Early and Late Conversion From Calcineurin Inhibitors to Everolimus in Heart Transplant Recipients—Results From Two Randomized Controlled Trials. Clinical Transplantation. 2026;40(10). doi:10.1111/ctr.70705

BibTeX
@article{Murbraech2026,
  author = {Murbraech, Klaus and Tecklzig, Feben and Massey, Richard John and Gude, Einar and Gustafsson, Finn and Eiskjær, Hans and Karason, Kristjan and Rådegran, Göran and Andreassen, Arne K and Gullestad, Lars and Broch, Kaspar},
  title = {Development in Left Ventricular Mass After Early and Late Conversion From Calcineurin Inhibitors to Everolimus in Heart Transplant Recipients—Results From Two Randomized Controlled Trials},
  journal = {Clinical Transplantation},
  year = {2026},
  volume = {40},
  number = {10},
  doi = {10.1111/ctr.70705}
}
Kostenlos starten →